MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis products. In addition, the company offers cannabis related medical information and services; and cannabis clinic services for patients requiring medical cannabis education and prescriptions. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.
Frequently asked questions
What sector does Medipharm Labs Corp (LABS) operate in?
Medipharm Labs Corp belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Medipharm Labs Corp (LABS) current stock price?
As of the latest data, Medipharm Labs Corp stock price is CA$0.06, with a previous close of CA$0.07. Medipharm Labs Corp lost -CA$0.01 in the last trading session, representing a -7.69% loss.
What is Medipharm Labs Corp (LABS) current market capitalization?
Medipharm Labs Corp market cap is approximately 25.63 million.
What is Medipharm Labs Corp (LABS) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.01, and the forward EPS is -CA$0.01.
What is Medipharm Labs Corp (LABS) EBITDA?
Medipharm Labs Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 221.00 thousand.
Does Medipharm Labs Corp (LABS) pay dividends?
No. Medipharm Labs Corp does not pay a dividend.
When is Medipharm Labs Corp (LABS) next earnings report?
Medipharm Labs Corp is expected to release its next earnings report on September 30, 2026.
What is Medipharm Labs Corp (LABS) beta (volatility) score?
Medipharm Labs Corp has a beta of 0.930, meaning its volatility is roughly in line with the market.
